- UPDATE: FDA disputes Capricor's claims of Phase 3 success for DMD cell therapyIn briefing documents published Monday ahead of an advisory committee meeting for deramiocel, the FDA disagreed with Capricor's assertion that a Phase 3 trial met its primary outcome measures.
- Lilly, AbbVie and others pursue in-vivo CAR-T, but safety concerns loomAnalysts at H.C. Wainwright say safety will be the decisive factor for in‑vivo CAR‑T therapies, noting that convenience and efficacy alone will not win over investors. In‑vivo CAR‑T aims to genera…